However, in tumour tissue from patients with NASH-induced HCC—treated with anti-PD1 therapy—we found increased numbers of intra-tumoral PD1+ cells compared to patients with HCC and viral hepatitis (Extended Data Fig. 10f). This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatohepatitis.